相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant
Hemanth K. Potluri et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications
Jhalak Dholakia et al.
CURRENT ONCOLOGY REPORTS (2022)
Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents
Jason M. Hafron et al.
ADVANCES IN THERAPY (2022)
Current and emerging therapies for neuroendocrine prostate cancer
Busola Ruth Alabi et al.
PHARMACOLOGY & THERAPEUTICS (2022)
Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
Johannes Czernin et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Boosting immune response with GM-CSF optimizes primary cryotherapy outcomes in the treatment of prostate cancer: a prospective randomized clinical trial
Al Baha Barqawi et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2021)
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
Ravi A. Madan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study
Huanyi Lin et al.
BMC CANCER (2021)
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naive metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
Sumit K. Subudhi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
KEYNOTE-641: Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer
Julie N. Graff et al.
FUTURE ONCOLOGY (2021)
Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
Hillard M. Lazarus et al.
FRONTIERS IN IMMUNOLOGY (2021)
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
Russell K. Pachynski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel
Masanori Noguchi et al.
ONCOLOGY REPORTS (2021)
A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer
Ashley E. Ross et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
Padmanee Sharma et al.
CLINICAL CANCER RESEARCH (2020)
Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa).
Katherine L. Paweletz et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Next generation of anti-immune checkpoints antibodies
Nathalie Bonnefoy et al.
M S-MEDECINE SCIENCES (2020)
Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
Evan Y. Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Basic principles of immunotherapy
Georgia Schilling et al.
RADIOLOGE (2020)
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
Karim Fizazi et al.
EUROPEAN UROLOGY (2020)
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update
Christo Kole et al.
CANCERS (2020)
Treatment of Advanced Prostate Cancer
Min Yuen Teo et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
James L. Gulley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization
Melissa A. Reimers et al.
CURRENT UROLOGY REPORTS (2019)
CAR-T cell therapy: a potential new strategy against prostate cancer
Giuseppe Schepisi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang et al.
MOLECULAR CANCER (2019)
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer
Douglas G. McNeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A. R. Hansen et al.
ANNALS OF ONCOLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Pedro Isaacsson Velho et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Combination immunotherapy: Taking Cancer vaccines to the next Level
Jeremy M. Grenier et al.
FRONTIERS IN IMMUNOLOGY (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Cancer-related morbidity at the end of life in men with prostate cancer.
Divya Yerramilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Application of atomic force microscopy in cancer research
Xiangying Deng et al.
JOURNAL OF NANOBIOTECHNOLOGY (2018)
Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD)
Brian M. Olson et al.
PROSTATE (2017)
Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
Richard P. Junghans et al.
PROSTATE (2016)
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
Edgardo D. Carosella et al.
EUROPEAN UROLOGY (2015)
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models
Gaia Zuccolotto et al.
PLOS ONE (2014)
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer
Brian M. Olson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model
Andressa Ardiani et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk Clinically Localized Prostate Cancer
Jacqueline Vuky et al.
ONCOLOGIST (2013)
Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
Paul F. Schellhammer et al.
UROLOGY (2013)
Personalized peptide vaccination A novel immunotherapeutic approach for advanced cancer
Tetsuro Sasada et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)
LE Johnson et al.
VACCINE (2006)
分享论文
